MassDevice

Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2

Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system.
MassDevice

Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap

Insulet (Nasdaq:PODD) today hosted its Investor Day event, led by CEO Ashley McEvoy, laying out the future for the insulin ...
Monthly Prescribing Reference

FDA Clears Omnipod 5 Tubeless Insulin System for Diabetes Management

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...
MobiHealthNews

Insulet scores FDA greenlight for Omnipod 5 insulin delivery system

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
InfoWorld

Update: Omnipod beefs up instant messaging service

Omnipod, which provides hosted instant message (IM) services to companies of all sizes, is preparing several enhancements to its platform, including the additions of a Web-based client, a telephony ...
Monthly Prescribing Reference

Omnipod 5 Tubeless Automated Insulin Delivery System Cleared for Younger Kids

The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...
The American Journal of Managed Care

Results of Omnipod 5 Type 2 Feasbility Study Presented at ATTD

Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and reduced ...
Yahoo Finance

Insulet’s Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years

ACTON, Mass., June 26, 2021--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...
Business Wire

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
The American Journal of Managed Care

Omnipod 5 May Improve Psychosocial Outcomes for Patients With T1D, Study Suggests

Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...
Business Wire

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...